Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Hoppensteadt, DA' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 81 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Kaiser, B; Hoppensteadt, DA; Fareed, J
      Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    2. Kanabrocki, EL; George, M; Hermida, RC; Messmore, HL; Ryan, MD; Ayala, DE; Hoppensteadt, DA; Fareed, J; Bremner, FW; Third, JLHC; Shirazi, P; Nemchausky, BA
      Day-night variations in blood levels of nitric oxide, T-TFPI, and E-selectin

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    3. Cella, G; Sbarai, A; Mazzaro, G; Motta, G; Carraro, P; Andreozzi, GM; Hoppensteadt, DA; Fareed, J
      Tissue factor pathway inhibitor release induced by defibrotide and heparins

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    4. Demir, M; Iqbal, O; Hoppensteadt, DA; Piccolo, P; Ahmad, S; Schultz, CL; Linhardt, RJ; Fareed, J
      Anticoagulant and antiprotease profiles of a novel natural heparinomimeticmannopentaose phosphate sulfate (PI-88)

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    5. Santillan, MKO; Herring, J; Hoppensteadt, DA; Jeske, W; Herbert, JM; Fareed, J
      The effect of a novel glycoprotein IIb/IIIa antagonist, SR 121566A, on platelet aggregation and activation in rhesus monkeys

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    6. Demir, M; Iqbal, O; Untch, B; Hoppensteadt, DA; Gaikwad, BS; Fareed, J
      Ecarin clotting time is sensitive to heparinoids: Comparison of two different techniques

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    7. Demir, M; Iqbal, O; Dietrich, CP; Hoppensteadt, DA; Ahmad, S; Daud, AN; Fareed, J
      Anticoagulant and antiprotease effects of a novel heparinlike compound from shrimp (Penaeus brasiliensis) and its neutralization by heparinase I

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    8. Hakki, SI; Fareed, J; Hoppensteadt, DA; Abdullah, H; Camblin, J; Nasseri, AF; Hamadeh, O; Wright, T
      Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery (vol 6, pg 206, 2000)

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    9. Hoppensteadt, DA; Fareed, J; Raake, P; Raake, W
      Endogenous release of tissue factor pathway inhibitor by topical application of an ointment containing mucopolysaccharide polysulfate to nonhuman primates

      THROMBOSIS RESEARCH
    10. Fareed, J; Shaikh, T; Hoppensteadt, DA
      Antithrombin and anti-Xa agents in the control of thrombogenesis

      PHARMAZIE
    11. Fareed, J; Hoppensteadt, DA; Bacher, P; Messmore, HL
      Antithrombin agents: The new class of antithrombotic drugs

      EVIDENCE-BASED MANAGEMENT OF THE ACUTE CORONARY SYNDROME
    12. Iqbal, O; Demir, AM; Hoppensteadt, DA; Wehrmacher, WH; Messmore, HL; Fareed, J
      Thrombolytic therapy in acute coronary syndrome

      EVIDENCE-BASED MANAGEMENT OF THE ACUTE CORONARY SYNDROME
    13. Gerbutavicius, R; Iqbal, O; Messmore, H; Hoppensteadt, DA; Demir, M; Khan, E; Bacher, P; Fareed, J
      Differential effects of unfractionated heparin and low-molecular-weight heparins on tissue thromboplastin inhibition test

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    14. Hakki, SI; Fareed, J; Hoppensteadt, DA; Abdullah, H; Camblin, J; Nasseri, AF; Hamadeh, O; Wright, T
      Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    15. Amin, HM; Ahmad, S; Walenga, JM; Hoppensteadt, DA; Leitz, H; Fareed, J
      Soluble P-selectin in human plasma: Effect of anticoagulant matrix and itslevels in patients with cardiovascular disorders

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    16. Ahmad, S; Yang, LH; Ahsan, A; Fu, K; Iqbal, O; Hoppensteadt, DA; Lewis, BE; Walenga, JM; Fareed, J
      Pharmacokinetics of argatroban in primates: Evidence on endogenous uptake

      INTERNATIONAL ANGIOLOGY
    17. Kanabrocki, EL; Third, JLHC; Ryan, MD; Nemchausky, BA; Shirazi, P; Scheving, LE; McCormick, JB; Hermida, RC; Bremner, WF; Hoppensteadt, DA; Fareed, J; Olwin, JH
      Circadian relationship of serum uric acid and nitric oxide

      JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    18. Izban, KF; Lietz, HW; Hoppensteadt, DA; Jeske, WP; Fareed, J; Bakhos, M; Walenga, JM
      Letter to the editor - The authors' response

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    19. Fareed, J; Hoppensteadt, DA; Bick, RL
      An update on heparins at the beginning of the new millennium

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    20. Fareed, J; Hoppensteadt, DA
      Heparins in the new millennium: Will unfractionated heparin survive? Epilogue

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    21. Jeske, W; Hoppensteadt, DA; Pifarre, R; Walenga, JM; Fareed, J
      Mechanism of blood coagulation. Newer aspects of anticoagulant and antithrombotic therapy

      ACUTE PULMONARY EMBOLISM
    22. Ahmad, S; Jeske, WP; Walenga, JM; Hoppensteadt, DA; Wood, JJ; Herbert, JM; Messmore, HL; Fareed, J
      Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    23. Fareed, J; Hoppensteadt, DA; Leya, F; Lewis, B; Callas, D; Wolf, H; Bick, RL
      Thrombogenesis in myocardial infarction and related syndromes: The role ofmolecular markers in diagnosis and management

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    24. Fareed, J; Walenga, JM; Hoppensteadt, DA; Jeske, WP; Ahmad, S; Lietz, H; McKenna, R; Messmore, HL; Haas, S
      Soluble adhesion molecules in the HIT syndrome: Pathophysiologic role and therapeutic modulation

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    25. Fareed, J; Lewis, BE; Callas, DD; Hoppensteadt, DA; Walenga, JM; Bick, RL
      Antithrombin agents: The new class of anticoagulant and antithrombotic drugs

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    26. Ahmad, S; Iqbal, O; Ahsan, A; Hoppensteadt, DA; Lewis, BE; Walenga, JM; Fareed, J
      Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using High Performance Liquid Chromatography and functional methods

      INTERNATIONAL ANGIOLOGY
    27. Fareed, J; Hoppensteadt, DA; Jeske, WP; Ahmad, S; Bick, RL
      Acquired defects of fibrinolysis associated with thrombosis

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    28. Fareed, J; Walenga, JM; Hoppensteadt, DA; Jeske, WP; Lietz, H; Ahmad, S; Callas, D; Messmore, HL; Haas, S
      Selectins in the HIT syndrome: Pathophysiologic role and therapeutic modulation

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    29. Izban, KF; Lietz, HW; Hoppensteadt, DA; Jeske, WP; Fareed, J; Bakhos, M; Walenga, JM
      Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis ofheparin-induced thrombocytopenia

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    30. Walenga, JM; Fasanella, AR; Iqbal, O; Hoppensteadt, DA; Ahmad, S; Wallis, DE; Bakhos, M
      Coagulation laboratory testing in patients treated with argatroban

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    31. Hoppensteadt, DA; Jeske, WP; Walenga, JM; Fu, KD; Yang, LH; Ing, TS; Herbert, JM; Fareed, J
      Laboratory monitoring of pentasaccharide in a dog model of hemodialysis

      THROMBOSIS RESEARCH
    32. Fareed, J; Callas, D; Hoppensteadt, DA; Lewis, BE; Bick, RL; Walenga, JM
      Antithrombin agents as anticoagulants and antithrombotics: Implications indrug development

      SEMINARS IN HEMATOLOGY
    33. Rabah, MM; Premmereur, J; Graham, M; Fareed, J; Hoppensteadt, DA; Grines, LL; Grines, CL
      Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris

      AMERICAN JOURNAL OF CARDIOLOGY
    34. AHMAD S; AHSAN A; IQBAL O; HOPPENSTEADT DA; LEWIS BE; WALENGA JM; FAREED J
      PHARMACOKINETICS AND PHARMACODYNAMICS OF ARGATROBAN AS STUDIED BY HPLC AND FUNCTIONAL METHODS - IMPLICATIONS IN THE MONITORING AND DOSAGE-OPTIMIZATIONS IN CARDIOVASCULAR PATIENTS

      Clinical and applied thrombosis/hemostasis
    35. KAISER B; GLUSA E; HOPPENSTEADT DA; BREDDIN HK; AMIRAL J; FAREED J
      A SUPERSULFATED LOW-MOLECULAR-WEIGHT HEPARIN (IK-SSH) INCREASES PLASMA-LEVELS OF FREE AND TOTAL TISSUE FACTOR PATHWAY INHIBITOR AFTER INTRAVENOUS AND SUBCUTANEOUS ADMINISTRATION IN HUMANS

      Blood coagulation & fibrinolysis
    36. GEORGE M; HOPPENSTEADT DA; LIETZ H; AHMAD S; FAREED J
      PERFORMANCE-CHARACTERISTICS OF 2 ELISA-BASED METHODS FOR THE QUANTITATION OF SOLUBLE THROMBOMODULIN IN PLASMA

      The FASEB journal
    37. AMIN HM; LIETZ H; HOPPENSTEADT DA; WALENGA JM; GEORGE M; AHMAD S; FAREED J
      QUANTITATION OF SOLUBLE P-SELECTIN IN HUMAN PLASMA - EFFECT OF ANTICOAGULANT MATRIX AND PRELIMINARY CLINICAL-DATA

      The FASEB journal
    38. AHMAD S; AHSAN A; IQBAL O; HOPPENSTEADT DA; LEWIS BE; WALENGA JM; FAREED J
      PHARMACOKINETICS AND PHARMACODYNAMICS OF A SYNTHETIC ANTITHROMBIN AGENT, ARGATROBAN, IN MAN AS STUDIED BY HPLC AND FUNCTIONAL METHODS - IMPLICATIONS IN THE MONITORING AND DOSAGE-OPTIMIZATIONS IN CARDIOVASCULARPATIENTS

      The FASEB journal
    39. FAREED J; CALLAS D; HOPPENSTEADT DA; WALENGA JM; BICK RL
      ANTITHROMBIN AGENTS AS ANTICOAGULANTS AND ANTITHROMBOTICS - IMPLICATIONS IN DRUG DEVELOPMENT

      The Medical clinics of North America
    40. FAREED J; HOPPENSTEADT DA; LEYA F; IQBAL O; WOLF H; BICK R
      USEFUL LABORATORY TESTS FOR STUDYING THROMBOGENESIS IN ACUTE CARDIAC SYNDROMES

      Clinical chemistry
    41. FAREED J; HOPPENSTEADT DA; JESKE W; AMIRAL J; WALENGA JM
      NON-HEPARIN GLYCOSAMINOGLYCANS-INDUCED GENERATION OF ANTIPLATELET FACTOR-4 HEPARIN ANTIBODIES - IMPLICATIONS IN THE MANAGEMENT OF HIT SYNDROME

      Clinical chemistry
    42. IQBAL O; AHMAD S; HOPPENSTEADT DA; LEWIS BE; FAREED J
      SPECIFIC QUANTITATION OF THROMBIN INHIBITORS USING ECARIN CLOTTING TIME - APPLICATION IN POINT OF CARE TESTING

      Clinical chemistry
    43. AMIN HM; LIETZ H; HOPPENSTEADT DA; WALENGA JM; GEORGE M; AHMAD S; FAREED J
      IMMUNOQUANTITATION OF SOLUBLE P-SELECTIN IN HUMAN PLASMA - EFFECT OF ANTICOAGULANT MATRIX AND PRELIMINARY CLINICAL-DATA

      Clinical chemistry
    44. GEORGE M; HOPPENSTEADT DA; LIETZ H; AHMAD S; AMIRAL J; FAREED J
      STUDIES ON THE PERFORMANCE-CHARACTERISTICS OF 2 ELISA-BASED METHODS FOR THE QUANTITATION OF SOLUBLE THROMBOMODULIN IN PLASMA

      Clinical chemistry
    45. AHMAD S; AHSAN A; IQBAL O; HOPPENSTEADT DA; LEWIS BE; WALENGA JM; FAREED J
      PHARMACOKINETICS AND PHARMACODYNAMICS OF A SYNTHETIC ANTITHROMBIN AGENT, ARGATROBAN, IN MAN AS STUDIED BY HPLC AND FUNCTIONAL METHODS - IMPLICATIONS IN THE MONITORING AND DOSAGE-OPTIMIZATIONS IN CARDIOVASCULARPATIENTS

      Clinical chemistry
    46. SHEIKH A; YANG LH; FU KD; HOPPENSTEADT DA; AHMAD S; FAREED J
      MONITORING OF THE ANTIPLATELET EFFECT OF GP IIB IIIA INHIBITOR USING FROZEN PLATELET-POOR PLASMA COLLECTED AFTER INTRAVENOUS AND SUBCUTANEOUS ADMINISTRATION IN PRIMATES/

      Clinical chemistry
    47. HOPPENSTEADT DA; JESKE WP; WALENGA JM; FU KD; YANG LH; ING T; HERBERT JM; FAREED J
      EFFICACY OF PENTASACCHARIDE IN A DOG-MODEL OF HEMODIALYSIS

      Thrombosis research
    48. HOPPENSTEADT DA; KAHN S; FAREED J
      FACTOR-X VALUES AS A MEANS TO ASSESS THE EXTENT OF ORAL ANTICOAGULATION IN PATIENTS RECEIVING ANTITHROMBIN DRUGS

      Clinical chemistry
    49. KAISER B; GLUSA E; LIETZ H; HOPPENSTEADT DA; BREDDIN HK; AMIRAL J; FAREED J
      A LOW-MOLECULAR-WEIGHT HYPERSULFATED HEPARIN DERIVATIVE WITH LOW ANTICOAGULANT ACTIVITY RELEASES VASCULAR TISSUE FACTOR PATHWAY INHIBITOR (TFPI) - STUDIES ON TOTAL AND FREE TFPI

      Blood
    50. JACOBS DG; PIOTROWSKI JJ; HOPPENSTEADT DA; SALVATOR AE; FAREED J
      INTERMITTENT PNEUMATIC COMPRESSION AND FIBRINOLYSIS - DESCRIPTION OF A NEW MODEL

      International angiology
    51. HOPPENSTEADT DA; JESKE W; FAREED J; NICOLAIDES AN
      PHYSICAL AND PHARMACOLOGICAL MANIPULATION OF THE VASCULAR SYSTEM AS MEASURED BY THE RELEASE OF TFPI AND OTHER MEDIATORS OF ANTITHROMBOTIC ACTIONS

      International angiology
    52. YANG LH; HOPPENSTEADT DA; IQBAL O; FAREED J
      DEFIBROTIDE MEDIATED INHIBITION OF SEROTONIN, ENDOTHELIN-I, THROMBOXANE, AND SERUM-INDUCED CONTRACTION OF CANINE FEMORAL AND PULMONARY ARTERIAL RINGS

      Thrombosis research
    53. FAREED J; WALENGA JM; JESKE W; KOZA MJ; HOPPENSTEADT DA; RAIBLE M; MESSMORE HL; BREDDIN K
      CLINICAL AND LABORATORY VALIDATION OF VARIOUS TESTS FOR THE DIAGNOSISOF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)

      Clinical chemistry
    54. WALENGA JM; HOPPENSTEADT DA; GRYZBAC M; MAY K; BLAKEMORE C; MANABAT N; MOLNAR J; BERMES EW
      EVALUATION OF THE STA AUTOMATED ANALYZER FOR HEMOSTASIS TESTING

      Clinical chemistry
    55. KAHN S; WOLF H; HOPPENSTEADT DA; WALENGA JM; GALBRAITH E; BERMES EW; FAREED J
      DIAGNOSTIC-VALUE OF TROPONIN-T AS A MARKER OF MYOCARDIAL INJURY IN ACUTE AND CHRONIC CORONARY SYNDROMES

      Clinical chemistry
    56. FASANELLA A; HOPPENSTEADT DA; WOLF H; BERMES EW; FAREED J
      PHARMACOKINETICS (PK) OF THE COMPARATIVE TFPI RELEASE BY LOW-MOLECULAR-WEIGHT HEPARINS (LMWHS) AS MEASURED BY USING A HIGHLY SENSITIVE ELISA METHOD

      Clinical chemistry
    57. KOZA MJ; HOPPENSTEADT DA; WALENGA JM; FAREED J; BERMES EW; PIFARRE R
      EFFECT OF A GLYCOPROTEIN IIB IIIA INHIBITOR ON PLATELET ACTIVATION AND AGGREGATION AS MEASURED BY AGGREGOMETRY AND WHOLE-BLOOD FLOW-CYTOMETRY/

      Clinical chemistry
    58. KOZA MJ; WALENGA JM; HOPPENSTEADT DA; BERMES EW; FAREED J
      MEASUREMENT OF THE ANTICOAGULANT EFFECT OF WARFARIN IN THE PRESENCE OF AN ANTITHROMBIN AGENT USING AMIDOLYTIC FACTOR-X ASSAY

      Clinical chemistry
    59. IQBAL O; HOPPENSTEADT DA; KOZA MJ; BERMES EW; WALENGA JM; FAREED J
      MOLECULAR MARKERS OF HEMOSTATIC AND VASCULAR ABBERATIONS IN THE ELDERLY AND THEIR PREDICTIVE VALUE FOR THE DIAGNOSIS OF THROMBOTIC DISORDERS

      Clinical chemistry
    60. JACOBS DG; PIOTROWSKI JJ; HOPPENSTEADT DA; SALVATOR AE; FAREED J
      HEMODYNAMIC AND FIBRINOLYTIC CONSEQUENCES OF INTERMITTENT PNEUMATIC COMPRESSION - PRELIMINARY-RESULTS

      The journal of trauma, injury, infection, and critical care
    61. FAREED J; BICK RL; HOPPENSTEADT DA; BERMES EW
      MOLECULAR MARKERS OF HEMOSTATIC ACTIVATION - APPLICATIONS IN THE DIAGNOSIS OF THROMBOSIS AND VASCULAR AND THROMBOTIC DISORDERS

      Clinical and applied thrombosis/hemostasis
    62. HOPPENSTEADT DA; JESKE W; FAREED J; BERMES EW
      THE ROLE OF TISSUE FACTOR PATHWAY INHIBITOR IN THE MEDIATION OF THE ANTITHROMBOTIC ACTIONS OF HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN

      Blood coagulation & fibrinolysis
    63. FAREED J; BICK RL; HOPPENSTEADT DA; WALENGA JM; MESSMORE HL; BERMES EW
      MOLECULAR MARKERS OF HEMOSTATIC ACTIVATION - IMPLICATIONS IN THE DIAGNOSIS OF THROMBOSIS, VASCULAR, AND CARDIOVASCULAR DISORDERS

      Clinics in laboratory medicine
    64. HOPPENSTEADT DA; FASANELLA A; FAREED J
      EFFECT OF PROTAMINE ON HEPARIN-RELEASABLE TFPI ANTIGEN LEVELS IN NORMAL VOLUNTEERS

      Thrombosis research
    65. HOPPENSTEADT DA; WALENGA JM; FASANELLA A; JESKE W; FAREED J
      TFPI ANTIGEN LEVELS IN NORMAL HUMAN VOLUNTEERS AFTER INTRAVENOUS AND SUBCUTANEOUS ADMINISTRATION OF UNFRACTIONATED HEPARIN AND A LOW-MOLECULAR-WEIGHT HEPARIN

      Thrombosis research
    66. HOPPENSTEADT DA; WALENGA JM; FAREED J; BERMES EW
      COMPARING R-TISSUE FACTOR AND MAMMALIAN TISSUE REAGENTS FOR PROTHROMBIN TIME

      Laboratory medicine
    67. WALENGA JM; HOPPENSTEADT DA; GRYZBAC M; MAY K; BLAKEMORE C; MANABAT N; MOLNAR J; BERMES EW
      EVALUATION OF THE STA AUTOMATED ANALYZER FOR HEMOSTASIS TESTING

      Blood
    68. FASANELLA T; HOPPENSTEADT DA; FAREED J; WOLF H
      INTRAVENOUS AND SUBCUTANEOUS PHARMACOKINETICS OF A LOW-MOLECULAR-WEIGHT HEPARIN (CERTOPARIN(R)) IN MAN

      Blood
    69. HOPPENSTEADT DA; BICK RL; JESKE W; NICOLAIDES AN; FAREED J
      PHYSICAL AND PHARMACOLOGICAL MODULATION OF THE VASCULAR SYSTEM AS MEASURED BY THE RELEASE OF TFPI, NO, TPA, AND PROSTACYCLIN AS MARKERS OF ENDOTHELIAL STIMULATION

      Blood
    70. KAISER B; HOPPENSTEADT DA; JESKE W; WUN TC; FAREED J
      INHIBITORY EFFECTS OF TFPI ON THROMBIN AND FACTOR XA GENERATION IN-VITRO - MODULATORY ACTION OF GLYCOSAMINOGLYCANS

      Thrombosis research
    71. FAREED J; PIFARRE R; LEYA F; HOPPENSTEADT DA; WALENGA JM; BICK RL
      PLATELET FACTOR-IV AND ANTITHROMBIN-III ARE NOT THE SOLE DETERMINANTSOF THE HEPARINIZATION RESPONSE

      Circulation
    72. FAREED J; PIFARRE R; LEYA F; HOPPENSTEADT DA; WALENGA JM; BICK RL
      PLATELET FACTOR-IV AND ANTITHROMBIN-III ARE NOT THE SOLE DETERMINANTSOF THE HEPARINIZATION RESPONSE

      Circulation
    73. HOPPENSTEADT DA; FAREED J; JESKE W; LEYA F; KOZA MJ; WALENGA JM; PIFARRE R
      RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR AS AN ANTITHROMBOTIC AND ANTICOAGULANT AGENT FOR INTERVENTIONAL CARDIOVASCULAR INDICATIONS

      Blood
    74. FAREED J; HOPPENSTEADT DA; WALENGA JM
      CURRENT PERSPECTIVES ON LOW-MOLECULAR-WEIGHT HEPARINS

      Seminars in thrombosis and hemostasis
    75. HOPPENSTEADT DA; JESKE W; AHSAN A; WALENGA JM; FAREED J
      BIOCHEMICAL AND PHARMACOLOGICAL PROFILE OF DEFINED MOLECULAR-WEIGHT FRACTIONS OF HEPARIN

      Seminars in thrombosis and hemostasis
    76. HOPPENSTEADT DA; HAAS S; BREDDIN HK; FAREED J
      MODULATION OF LABORATORY PARAMETERS AFTER THERAPEUTIC AND PROPHYLACTIC ADMINISTRATION OF SANDOPARIN

      Seminars in thrombosis and hemostasis
    77. LOJEWSKI B; BACHER P; IQBAL O; WALENGA JM; HOPPENSTEADT DA; LEYA F; FAREED J
      EVALUATION OF HEMATOLOGIC ALTERATIONS ASSOCIATED WITH DAILY ADMINISTRATION OF LOW-MOLECULAR-WEIGHT HEPARIN (MONO-EMBOLEX) FOR A 12-WEEK PERIOD

      Seminars in thrombosis and hemostasis
    78. CALLAS DD; HOPPENSTEADT DA; JESKE W; IQBAL O; BACHER P; AHSAN A; FAREED J
      COMPARATIVE PHARMACOLOGICAL PROFILE OF A GLYCOSAMINOGLYCAN MIXTURE, SULODEXIDE, AND A CHEMICALLY-MODIFIED HEPARIN DERIVATIVE, SULEPAROIDE

      Seminars in thrombosis and hemostasis
    79. MALINOWSKA K; IQBAL O; HOPPENSTEADT DA; WALENGA JM; FAREED J
      INVIVO STUDY OF BLEEDING AND ANTITHROMBOTIC EFFECTS OF LOW-MOLECULAR-WEIGHT HEPARIN ML-009723

      Seminars in thrombosis and hemostasis
    80. BACHER P; HORST B; BREYER HG; HOPPENSTEADT DA; WALENGA JM; FAREED J
      POSTOPERATIVE MONITORING OF LOW-MOLECULAR-WEIGHT HEPARIN-PROPHYLAXIS IN HIGH-RISK PATIENTS

      Seminars in thrombosis and hemostasis
    81. IQBAL O; JESKE W; BACHER P; HOPPENSTEADT DA; WALENGA JM; FAREED J
      A COMPARISON OF THE PHARMACOKINETIC AND PHARMACODYNAMIC PROFILES OF CLEXANE AND LOVENOX IN DOGS

      Seminars in thrombosis and hemostasis


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 11/08/20 alle ore 03:54:51